Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025

Evoke Pharma

13/11/2025 12:14

Overview

Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln

Company to be acquired by QOL Medical for $11.00 per share

Gimoti patent extended to November 2038, ensuring exclusivity

Outlook

Company expects acquisition by QOL Medical to close in Q4 2025

Company anticipates expanded distribution through new pharmacy relationships

Company believes acquisition will enhance growth potential under new leadership

Result Drivers

SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships

EXPANDED ACCESS - New pharmacy relationships with Omnicell and Brentwood Pharmacy enhance distribution

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.45
Q3 Net Income
-$1.20 mln
Q3 Operating Expenses
$5.40 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release: ID:nGNX80pkz3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)